Genetic Risk Model for In-stent Restenosis of Second-and Third-generation Drug-eluting Stents

Overview

Journal iScience

Publisher Cell Press

Date 2021 Sep 29

PMID 34585120

Citations 5

Authors

Yen-Wen Liu

Mu-Shiang Huang

Ling-Wei Hsu

Hsien-Yuan Chang

Cheng-Han Lee

Chi-Ying Lee

Dao-Peng Chen

Yi-Heng Li

Ting-Hsin Chao

Pei-Fang Su

Meng-Ru Shen

Ping-Yen Liu

Affiliations

Soon will be listed here.

Abstract

The new generation, i.e., second- and third-generation, drug-eluting stents (DESs) remain a risk of in-stent restenosis (ISR). We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation DES ISR. We enrolled patients with coronary artery disease (CAD) treated with new generations DESs by a single-center cohort study in Taiwan and evaluated their genetic profile. After propensity score matching, there were 343 patients and 153 patients in the derivation and validation cohorts, respectively. Five selected single-nucleotide polymorphisms (SNPs), i.e., SNPs in , , , , and S, were included to calculate the GRS for new generation DES ISR. In the derivation and the validation cohorts, patients with a GRS greater than or equal to 3 had significantly higher new generation DES ISR rates. We provide biological information for interventional cardiologists prior to percutaneous coronary intervention by specific five SNP-derived GRS.

Citing Articles

A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention.

Shahsanaei F, Gharibzadeh A, Behrooj S, Abbaszadeh S, Nourmohammadi M BMC Cardiovasc Disord. 2024; 24(1):304.

PMID: 38877398 PMC: 11177414. DOI: 10.1186/s12872-024-03955-3.

Application of genetic risk score for in-stent restenosis of second- and third-generation drug-eluting stents in geriatric patients.

Hsu Y, Huang M, Chang H, Lee C, Chen D, Li Y BMC Geriatr. 2023; 23(1):443.

PMID: 37468836 PMC: 10357661. DOI: 10.1186/s12877-023-04103-w.

Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients.

Al Hageh C, Chacar S, Venkatachalam T, Gauguier D, Abchee A, Chammas E Vasc Health Risk Manag. 2023; 19:83-92.

PMID: 36814994 PMC: 9940491. DOI: 10.2147/VHRM.S394695.

Bioimpedance Sensing of Implanted Stent Occlusions: Smart Stent.

Rodriguez A, Barroso P, Olmo A, Yufera A Biosensors (Basel). 2022; 12(6).

PMID: 35735563 PMC: 9221340. DOI: 10.3390/bios12060416.

Role of Glycosylation in Vascular Calcification.

Masbuchin A, Rohman M, Liu P Int J Mol Sci. 2021; 22(18).

PMID: 34575990 PMC: 8469761. DOI: 10.3390/ijms22189829.

References

Hsu L, Chen P, Chang W, Lee W, Liu P . The Role of ROCK in Platelet-Monocyte Collaborative Induction of Thromboinflammation during Acute Coronary Syndrome. Thromb Haemost. 2020; 120(10):1417-1431. DOI: 10.1055/s-0040-1714278. View

Guo S, Lopez-Ilasaca M, Dzau V . Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation. J Biol Chem. 2005; 280(13):12536-41. DOI: 10.1074/jbc.M500296200. View

Khera A, Emdin C, Drake I, Natarajan P, Bick A, Cook N . Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016; 375(24):2349-2358. PMC: 5338864. DOI: 10.1056/NEJMoa1605086. View

Bae N, Gao M, Li X, Premkumar T, Sbardella G, Chen J . A transcriptional coregulator, SPIN·DOC, attenuates the coactivator activity of Spindlin1. J Biol Chem. 2017; 292(51):20808-20817. PMC: 5743059. DOI: 10.1074/jbc.M117.814913. View

Roselli C, Chaffin M, Weng L, Aeschbacher S, Ahlberg G, Albert C . Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018; 50(9):1225-1233. PMC: 6136836. DOI: 10.1038/s41588-018-0133-9. View

Yuan X, Zhang T, Yao F, Liao Y, Liu F, Ren Z . THO Complex-Dependent Posttranscriptional Control Contributes to Vascular Smooth Muscle Cell Fate Decision. Circ Res. 2018; 123(5):538-549. DOI: 10.1161/CIRCRESAHA.118.313527. View

Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M . Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003; 3(1):1-19. DOI: 10.2174/1568009033333754. View

Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T . Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation. 2011; 125(4):584-91. DOI: 10.1161/CIRCULATIONAHA.111.046599. View

Lin M, Huang M, Liu C, Yang T, Huang M . GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol. 2014; 50(5):478-84. DOI: 10.1016/j.oraloncology.2014.02.003. View

10.

Dangas G, Claessen B, Caixeta A, Sanidas E, Mintz G, Mehran R . In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56(23):1897-907. DOI: 10.1016/j.jacc.2010.07.028. View

11.

Zhou X, Xu Y, Yin D, Zhao F, Hao Z, Zhong Y . Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2. Biomed Pharmacother. 2020; 131:110764. DOI: 10.1016/j.biopha.2020.110764. View

12.

Mega J, Stitziel N, Smith J, Chasman D, Caulfield M, Devlin J . Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015; 385(9984):2264-2271. PMC: 4608367. DOI: 10.1016/S0140-6736(14)61730-X. View

13.

Bonaa K, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O . Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. 2016; 375(13):1242-52. DOI: 10.1056/NEJMoa1607991. View

14.

Jin G, Long C, Liu W, Tang Y, Zhu Y, Zhou X . Identification and characterization of novel alternative splice variants of human SAMD11. Gene. 2013; 530(2):215-21. DOI: 10.1016/j.gene.2013.08.033. View

15.

Piccolo R, Stefanini G, Franzone A, Spitzer E, Blochlinger S, Heg D . Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv. 2015; 8(4). DOI: 10.1161/CIRCINTERVENTIONS.114.002223. View

16.

Hajek C, Guo X, Yao J, Hai Y, Johnson W, Frazier-Wood A . Coronary Heart Disease Genetic Risk Score Predicts Cardiovascular Disease Risk in Men, Not Women. Circ Genom Precis Med. 2018; 11(10):e002324. PMC: 6292435. DOI: 10.1161/CIRCGEN.118.002324. View

17.

Min L, Mogi M, Tamura K, Iwanami J, Sakata A, Fujita T . Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway. J Mol Cell Cardiol. 2009; 47(6):798-809. DOI: 10.1016/j.yjmcc.2009.09.006. View

18.

Verschuren J, Trompet S, Postmus I, Sampietro M, Heijmans B, Houwing-Duistermaat J . Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. PLoS One. 2012; 7(8):e42401. PMC: 3411750. DOI: 10.1371/journal.pone.0042401. View

19.

Otsuka Y, Ishiwata S, Inada T, Kanno H, Kyo E, Hayashi Y . Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance.... Eur Heart J. 2011; 32(7):829-37. DOI: 10.1093/eurheartj/ehq480. View

20.

Hu W, Yeh C, Liu S, Huang M, Lai I . The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities. Am J Cancer Res. 2018; 8(9):1739-1751. PMC: 6176175. View